Floatz logo

Magrolimab

Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8

National Cancer Institute (NCI)monoclonal_antibodyPhase 1/2Dormant
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 cohort.

Asset / SponsorPhaseRating
Romidepsin
Northwestern University
Phase 2BB
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
Pembrolizumab
University of Michigan Rogel Cancer Center
Phase 2BB
TACROLIMUS
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
MOGAMULIZUMAB
University of Michigan Rogel Cancer Center
Phase 2B

View all 29 →

Same molecule, other indications

Magrolimab is also rated in:

myelodysplastic syndromeDormant
CC
Indicative ·
44 / 100
View asset →
neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →